EXV-801
/ Exciva
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 05, 2026
SERENADA: Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
(clinicaltrials.gov)
- P2/3 | N=300 | Recruiting | Sponsor: Exciva GmbH | Not yet recruiting ➔ Recruiting | Trial completion date: Jun 2029 ➔ Feb 2029
Enrollment open • Trial completion date • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia
1 to 1
Of
1
Go to page
1